Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 309,749 | 133,820 | 419,665 | 61,861 | 176,328 |
| Marketable Securities | 8,873 | 9,000 | 282,298 | 486,316 | 571,594 |
| Receivables | 457,989 | 441,273 | 346,035 | 316,339 | 304,621 |
| Inventories | 155,467 | 176,475 | 185,796 | 181,505 | 164,868 |
| TOTAL | $1,003,036 | $825,207 | $1,328,749 | $1,122,673 | $1,262,028 |
| Non-Current Assets | |||||
| PPE Net | 82,230 | 82,137 | 71,420 | 71,520 | 72,816 |
| Intangibles | 1,534,278 | 1,561,827 | 765,365 | 783,127 | 800,889 |
| Other Non-Current Assets | 53,175 | 56,152 | 55,698 | 76,579 | 60,799 |
| TOTAL | $1,669,683 | $1,700,116 | $892,483 | $931,226 | $934,504 |
| Total Assets | $2,672,719 | $2,525,323 | $2,221,232 | $2,053,899 | $2,196,532 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 208,743 | N/A | 710,685 | N/A | N/A |
| Accounts payable and accrued liabilities | 14,098 | 20,899 | 15,360 | 18,691 | 20,074 |
| Accrued Expenses | 140,369 | 156,193 | 111,183 | 115,591 | 130,305 |
| TOTAL | $363,210 | $177,092 | $837,228 | $134,282 | $150,379 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,935,896 | 2,142,630 | 800,072 | 1,509,100 | 1,507,447 |
| Other Non-Current Liabilities | 106,448 | 113,863 | 71,799 | 77,769 | 56,436 |
| TOTAL | $2,089,873 | $2,299,417 | $880,089 | $1,586,869 | $1,563,883 |
| Total Liabilities | $2,453,083 | $2,476,509 | $1,717,317 | $1,721,151 | $1,714,262 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 118,613 | 118,017 | 117,597 | 116,966 | 123,221 |
| Common Shares | 118 | 118 | 118 | 118 | 123 |
| Retained earnings | 204,835 | 54,786 | 502,146 | 361,033 | 477,964 |
| Other shareholders' equity | -12,703 | -18,092 | -22,258 | -28,403 | -3,413 |
| TOTAL | $219,636 | $48,814 | $503,915 | $332,748 | $482,270 |
| Total Liabilities And Equity | $2,672,719 | $2,525,323 | $2,221,232 | $2,053,899 | $2,196,532 |